Sheng-Kwei Song

The committees determined Dr. Song’s personal financial relationship with DxGPS, related to the above referenced research, creates a financial conflict of interest due to the following reasons:

• Dr. Song’s personal financial relationship is related to the research because the research is evaluating a product licensed by DxGPS.

• Dr. Song is entitled to future royalties from the licensing of the IP, which is evaluated in the above listed research being conducted at WU

• The primary focus of DxGPS, an entity with which Dr. Song owns equity, is to commercialize the D-Histo IP, which is a code correction for the DBSI IP being developed and evaluated in the research listed above.

• The outcomes of the research could directly benefit DxGPS.

• Since Dr. Song owns equity in the company, Dr. Song could directly benefit should the company’s equity value increase as a result of the study.

• Dr. Song’s role, as identified below, could directly affect the study.

While the committees determined financial conflicts of interest exist, they concluded sufficient mechanisms exist to ensure the objectivity and integrity of the research and adequate protections are in place for the human research participants, based on the following reasons:

• Dr. Song is uniquely qualified by virtue of his expertise and experience, and the research could not be conducted as effectively without his involvement.

• There will be non-conflicted individuals involved in the data collection and data analysis.

• The clinical studies are low-risk to patients and will not be used to impact clinical care.

• The preclinical research is basic and in its early stages

• The studies are evaluating the DBSI IP, which may have limited benefit to the development of D-Histo, the primary purpose of DxGPS.

• Additionally, a plan has been developed to mitigate the financial conflicts of interest, which is outlined below.